Two more biotechs have signaled their intention to go public, adding to what Fierce Biotech describes as a stampede of IPO filings. TRex Bio, which counts Eli Lilly as a backer, and Retension Pharmaceuticals, a company focused on hypertension, have both set out plans for public listings this year.
The report does not include financial details such as proposed share prices, target valuations, or expected timelines. It notes only that the two companies are the latest in a series of biotech firms moving toward the public markets.
With this news, the biotech IPO pipeline continues to grow, though the source does not compare the two companies' strategies or business models beyond their basic focus areas.